Serine Proteinase Inhibitors
"Serine Proteinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Exogenous or endogenous compounds which inhibit SERINE ENDOPEPTIDASES.
| Descriptor ID |
D015842
|
| MeSH Number(s) |
D27.505.519.389.745.800
|
| Concept/Terms |
Serine Proteinase Inhibitors- Serine Proteinase Inhibitors
- Serine Proteinase Antagonists
- Serine Endopeptidase Inhibitors
- Serine Protease Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Serine Proteinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Serine Proteinase Inhibitors".
This graph shows the total number of publications written about "Serine Proteinase Inhibitors" by people in this website by year, and whether "Serine Proteinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 2 | 0 | 2 |
| 1998 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 0 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serine Proteinase Inhibitors" by people in Profiles.
-
Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability to probe its latency transition. J Biol Chem. 2022 12; 298(12):102608.
-
Isolation and functional diversity of Bowman-Birk type serine proteinase inhibitors from Hyacinthus orientalis. Biochem J. 2021 03 26; 478(6):1287-1301.
-
Synthesis, Structure-Activity Relationships, and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease. J Med Chem. 2021 03 11; 64(5):2777-2800.
-
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovasc Disord. 2019 10 29; 19(1):240.
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
-
Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
-
Therapeutically Targeting Platelet-Derived Growth Factor-Mediated Signaling Underlying the Pathogenesis of Subarachnoid Hemorrhage-Related Vasospasm. J Stroke Cerebrovasc Dis. 2018 Sep; 27(9):2289-2295.
-
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. J Clin Lipidol. 2018 Sep - Oct; 12(5):1141-1145.
-
Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
-
A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. J Clin Lipidol. 2017 May - Jun; 11(3):596-599.